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OBJECTIVE — To understand physician behaviors and attitudes in managing children with
type 2 diabetes.
RESEARCH DESIGN AND METHODS — A survey was mailed to a nationwide sample
of pediatric endocrinologists (PEs).
RESULTS — A total of 40% of PEs surveyed responded (211 of 527). Concordance with
current monitoring guidelines varied widely, ranging from 36% (foot care) to 93% (blood
pressure monitoring). Given clinical vignettes addressing hyperlipidemia, hypertension, and
microalbuminuria, only 34% of PEs were fully concordant with current treatment guidelines.
Reported barriers included concerns about patient adherence, insufﬁcient scientiﬁc evidence
about treatment, and lack of familiarity with current recommendations. Providers aged 45
years or in clinical practice 10 years reported signiﬁcantly more aggressive management
behaviors and had higher concordance with guidelines.
CONCLUSIONS — Screening and management of pediatric type 2 diabetes varied widely
among PEs, suggesting opportunities for quality improvement. More aggressive management of
type 2 diabetes among younger providers may be related to recent training when type 2 diabetes
was more common.
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T
he incidence of type 2 diabetes in
children is increasing (1), and chil-
drenwithtype2diabetesareathigh
risktodevelopdiabetes-relatedcomplica-
tions, including hyperlipidemia, hyper-
tension, and microalbuminuria (2–4).
Despite limited scientiﬁc evidence, sev-
eral consensus statements on the assess-
mentandmanagementofpediatrictype2
diabetes have been developed (4–6).
Currentunderstandingofphysicianman-
agement of pediatric type 2 diabetes is
limited(7–10).Weconductedasurveyto
better understand pediatric endocrinolo-
gists’ (PEs’) behaviors and attitudes re-
lated to the management of pediatric type
2 diabetes.
RESEARCH DESIGN AND
METHODS— Experts in diabetes,
health behavior, and health services re-
search created a survey (online appendix
[available at http://care.diabetesjournals.
org/cgi/content/full/dc09-1333/DC1]) tar-
geted for PEs managing pediatric type 2
diabetes.Thesurveyincluded1)provider
characteristics,2)descriptionofclinicset-
ting and patient population, 3) frequency
of tests for care of type 2 diabetes, 4) case
vignettes related to management of co-
morbidities in type 2 diabetes, 5) medica-
tions prescribed for type 2 diabetes, 6)
attitudes and perceived barriers to the
management of type 2 diabetes, and 7)
clinic infrastructure for chronic disease
management(assessedusingasubscaleof
the Assessment of Chronic Illness Care
Scale [11]). Survey items were based on
current recommendations of the Ameri-
can Diabetes Association (ADA) (4,5) and
the National Heart, Lung, and Blood In-
stitute (NHLBI) guidelines for manage-
ment of hypertension in adolescents
(12). Three case vignettes to evaluate
providers’ management aggressiveness
included 1) a 15 year old with dyslipi-
demia, 2) a 14 year old with hyperten-
sion, and 3) a 17 year old with hyperten-
sion and microalbuminuira.
A master ﬁle containing addresses of
the nation’s PEs was obtained from the
AmericanMedicalAssociation.Halfofthe
PEs were randomly selected, and surveys
weremailedbetweenAugustandSeptem-
ber 2007. Responders had the option of
mailing back the survey or taking it on-
line (through www.surveymonkey.com).
Twoadditionalmailingsweresenttonon-
responders. The ﬁnal mailing offered a
$20 gift card for survey completion. The
VanderbiltInstitutionalReviewBoardap-
proved all aspects of the study.
Analyses were performed using
STATA 8.2 (College Park, TX). Descrip-
tive statistics were performed on all sur-
vey responses. In addition, each response
relatedtoscreeningortreatmentbehavior
was assigned a numeric value based on
screening frequency or aggressiveness of
treatment choice. Summary scores were
calculatedtomeasurethetotalaggressive-
nessforscreeningaswellasfortreatment.
Aggressiveness scores reﬂected the level
of care provided and did not necessarily
indicate the appropriateness of care. Each
response related to screening or treat-
ment behavior was also assigned a point
if it was deemed concordant with cur-
rent ADA or NHLBI guidelines. Sum-
mary scores were calculated to measure
thetotalconcordanceforscreening,and
for treatment. Analyses using t tests ex-
amined the relationship between pro-
vider characteristics and 1) their level of
monitoring or treatment aggressiveness
and 2) their level of concordance with
current guidelines.
RESULTS— Of 527 eligible surveys,
there were 210 responses (40%). Fifty
percent were from female subjects, 53%
●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●
From the
1Departments of Medicine and Pediatrics, Vanderbilt University, Nashville, Tennessee; the
2Vanderbilt Eskind Diabetes Clinic, Vanderbilt University, Nashville, Tennessee; the
3Vanderbilt Univer-
sity School of Nursing, Nashville, Tennessee; and the
4Department of Psychology, Vanderbilt University,
Nashville, Tennessee.
Corresponding author: Russell Rothman, russell.rothman@vanderbilt.edu.
Received 21 July 2009 and accepted 17 November 2009. Published ahead of print at http://care.
diabetesjournals.org on 10 December 2009. DOI: 10.2337/dc09-1333.
© 2010 by the American Diabetes Association. Readers may use this article as long as the work is properly
cited, the use is educational and not for proﬁt, and the work is not altered. See http://creativecommons.
org/licenses/by-nc-nd/3.0/ for details.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby
marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Clinical Care/Education/Nutrition/Psychosocial Research
BRIEF REPORT
512 DIABETES CARE, VOLUME 33, NUMBER 3, MARCH 2010 care.diabetesjournals.orgwere from subjects aged 26–45 years,
and74%werefromwhitesubjects.Atotal
of 71% completed medical school in the
U.S.; and 35% had practiced postfellow-
ship for 5 years; 52% described them-
selves as a clinician, 20% as a researcher,
13% as a clinician-educator, and 12% as
current fellows; and 45% of providers re-
ported caring for three or more patients
with type 2 diabetes weekly.
There was a wide range of practices
for monitoring and management related
to type 2 diabetes (Table 1). For example,
43% were not in concordance for annual
liver function test screenings, 64% for an-
nual foot exams, 23% for annual retinal
exams, 28% for lipid panels, and 14% for
annual microalbumin screenings. While
25% of physicians would start lipid-
lowering medication with an LDL of 140
mg/dl, 20% of physicians would not start
a lipid-lowering medication with an LDL
of 170 mg/dl. For hypertension manage-
ment, 19.5% of the responses were not
concordant with current guidelines on
treating a patient with blood pressure at
the 99th percentile. Similarly, 18.5% of
the responses were not concordant with
guidelinesforapatientwithbloodpres-
sure at the 99th percentile and mi-
croalbuminuria. Only 34% of PEs were
fully concordant with all of the current
guideline recommendations for lipid,
blood pressure, and microalbuminuria
management.
For lipid management, the top three
perceived barriers were difﬁculties mak-
ing lifestyle changes in patients (78%),
insufﬁcient evidence about best manage-
ment practice (71%), and providers’ lack
of familiarity with subject matter (47%).
For hypertension management, the top
three barriers were difﬁculty making life-
style changes in patients (67%), concerns
about patient compliance (55%), and in-
sufﬁcientscientiﬁcevidenceforbestman-
agement practice (46%).
Younger providers (aged 45 years)
and female physicians were associated
(P  0.05) with more aggressive screen-
ing/monitoring practices. U.S. medical
graduates, physicians with clinical prac-
tice 10 years, or providers with lack of
board certiﬁcation were more aggressive
in reported treatment of hyperlipidemia,
hypertension, and microalbuminuria.
Younger providers (aged 45 years) and
those in clinical practice 10 years were
modestly associated with higher concor-
dance with guidelines for screening.
CONCLUSIONS — The results of
this study demonstrate that there is wide
variation in how PEs are managing pedi-
atric type 2 diabetes. This variation is
often nonconcordant with current guide-
lines set forth by the ADA and other ex-
pert panels. Possible reasons for the
variation in testing and treatment in-
clude clinical inertia (13), lack of famil-
iarity with current recommendations
(14), pediatric endocrinologists’ lack of
experience with antihypertensive and
cholesterol-lowering medications (14),
lack of system-level approaches (15), and
the current lack of rigorous scientiﬁc evi-
dence to support aggressive medication
therapy in adolescents (14). Additionally,
Table 1—Screening, monitoring, and treatment practices (percent of responding endocrinologists endorsing)
Frequency of testing
Every  3 months Every 6 months Every 1 year Every 2 years Not used
Screening/monitoring tests
A1C 91.5* 7.5 0 0 1
Blood pressure 93* 6.5 0 0 0.5
Fasting lipid panel 2.5 15 72.5* 9* 1
Retinal exam 5.5 0.5 77* 11 6
Foot exam 28 12 35.5* 8 16
Liver function tests 7.5 20 57* 8.5 7
Microalbumin test 5.5 4.5 86* 2.5 1.5
LDL level at:
110 mg/dl 140 mg/dl 170 mg/dl
Treatment of hyperlipidemia
Continue lifestyle change, recheck every 3 months 55* 18* 2
Refer to dietitian/physical therapist 39* 45* 18
Start lipid medications 2 25 50*
Change intensity of medications 0 0.5 12*
Refer to lipid specialist 0 8* 17*
Systolic blood pressure at:
95% 99% 99%  microalbuminuria
Treatment of hypertension
Continue present management, follow up in 3–6 months 11* 4.5 0.5
Intensify lifestyle changes, follow up in 3–6 months 39* 7 5
Refer to dietitian and/or exercise physiologist 40* 8 13
Start or intensity blood pressure–lowering medications 7* 70* 71*
Data are percent. *Concordance with current guideline recommendations.
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this patient population is challenging,
andcliniciansmayfocusonglycemiccon-
trol with insufﬁcient consideration of
other issues. Younger PE’s association
with more aggressive screening and con-
cordancewithguidelinescouldberelated
togreaterexposuretotype2diabetesdur-
ing their training.
Nonresponder bias is an important
limitation of this study. Social desirability
bias is another limitation since we only
obtained provider’s self-reported behav-
iors and not their actual behaviors in
clinic. The wide variability seen in this
study suggests room for improvement in
current clinical practice. To achieve this
goal, further research is necessary to de-
termine the best management options in
this high-risk population. Hopefully,
studies such as the ongoing National In-
stitutes of Health–funded Treatment Op-
tions for Type 2 Diabetes in Adolescents
and Youth Study will help to address this
challenge.
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